patent infringement

Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.

In their complaint the plaintiffs claimed Illumina fraudulently obtained two US patents by concealing a reference from the patent office.

CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.

Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."

Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.

The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.

News items for the week of August 10, 2020.

Carlsbad, California-based BioSpyder said that HTG has repeatedly and baselessly accused it of infringing HTG's patent for quantitative nuclease protection assay and sequencing improvements.

The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.